Engineered T cells may be harnessed to kill solid tumor cells

There is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherapy is still the most widely used cancer treatment, but chemotherapy attacks all the rapidly dividing cells that it locates within the body, whether they’re ultimately harmful or beneficial. A new Tel Aviv University study led by Dr. Yaron Carmi […]

Read more

Immunologists identify T cell homing beacons for lungs

Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza. The findings were published online Thursday, September 26 in Journal of Experimental Medicine. Much research on immunity to influenza virus focuses on antibodies, infection- […]

Read more

CAR T cell therapy: On the cusp of ‘an immunotherapy revolution’?

A deeper understanding of the immune system’s role in controlling cancer has helped drive “an immunotherapy revolution,” offering hope for many patients with previously incurable cancers, including children, doctors have concluded in a new report. The assessment, from two Stanford University doctors, is part of their broader analysis on lessons learned from “the first leg of the CAR T cell […]

Read more

New evidence shows cytotoxic T cells can identify, invade, and destroy targets of large mass like T. gondii tissue cysts

CD8+ cytotoxic T lymphocytes can kill host cells infected with various microorganisms as well as single individual cancer cells through direct cell-to-cell contact, but their ability to destroy a target of large mass remains unexplored. A study in The American Journal of Pathology provided novel evidence on the capability of the immune system to eliminate large parasite-filled cysts associated with […]

Read more

Reducing B cells with CAR T cells is effective treatment of experimental lupus

Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide a therapeutic option in lupus and pave the way for clinical […]

Read more

New two-year data show 39 percent of NHL patients treated with CAR T remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive. The new long-term safety and […]

Read more